When the duration of infusion does matter: The case of meropenem and piperacillin

Minerva Anestesiologica

Volumn 80, Issue 12, 2014, Pages 1258-1260

  Dimopoulos, G ^a   Matthaiou, D K ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; COLISTIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG MONITORING; EDITORIAL; HUMAN; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; TREATMENT DURATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; PIPERACILLIN;

EID: 84929353241     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Editorial

References (20)

1. De Waele J, Carlier M, Hoste E, Depuydt P, Decruyenaere J, Wallis SC et al. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiol 2014;80:1308-15.
2. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete A, Hoste E et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Critical care (London, England) 2013;17:R84.
3. Afaneh CI, Ho VP, McWhorter P, Nicolau DP, Barie PS. Minor fluctuations in renal function may alter therapeutic drug concentrations substantially during high-dose, continuous-infusion beta-lactam therapy for multi-drug-resistant Gram-negative bacilli. Surgical Infections 2012;13:415-7.
4. Akers KS, Niece KL, Chung KK, Cannon JW, Cota JM, Murray CK. (2014) Modified Augmented Renal Clearance score predicts rapid piperacillin and tazobactam clearance in critically ill surgery and trauma patients. J Trauma Acute Care Surg 2014;77 (3 Suppl 2):S163-70.
5. Bauer SR, Salem C, Connor MJ, Jr., Groszek J, Taylor ME, Wei P et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol 2012;7:452-7.
6. Isla A, Rodriguez-Gascon A, Troconiz IF, Bueno L, Solinis MA, Maynar J et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008;47:173-80.
7. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair R Cole L et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012;40:1523-8.
8. Langgartner J, Vasold A, Gluck T, Reng M, Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008;34:1091-6.
9. Asin-Prieto E, Rodriguez-Gascon A, Troconiz IF, Soraluce A, Maynar J, Sanchez-Izquierdo JA et al. Population pharmacokinetics of piperacillin and tazobactam in critica lly ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis. J Antimicrob Chemother 2014;69:180-9.
10. Duszynska W, Taccone FS, Switala M, Hurkacz M, Kowalska-Krochmal B, Kubler A. Continuous infusion of piperacillin/tazobactam in ventilator-associated pneumonia: a pilot study on efficacy and costs. Int J Antimicrob Agents 2012;39:153-8.
11. Lodise TP, Jr., Lomaestro B, Drusano GL. Piperacillintazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007;44:357-63.
12. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28:122-7
13. Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled ttial. Crit Care (London, England) 2012;16:R113
14. Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009;33:290-1.
15. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomeisall C et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013;56:236-44.
16. Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J et al. Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. IntJ Antimicrob Agents 2013;57:5811-9.
17. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE et al. Colistin therapy for microbiologically documented multidrug-resistant Gramnegative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrobial Agents 2010;35:194-9.
18. Levy Hara G, Gould I, Endimiani A, Pardo PR, Daikos G, Hsueh PR et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J Chemother 2013;25:129-40.
19. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010;65:1073-5.
20. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002;46:2327-32.